Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
1.080
-0.060 (-5.26%)
At close: Nov 20, 2024, 4:00 PM
1.140
+0.060 (5.56%)
After-hours: Nov 20, 2024, 4:39 PM EST
Onconetix Revenue
Onconetix had revenue of $704.85K in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $1.46M. In the year 2023, Onconetix had annual revenue of $58.47K.
Revenue (ttm)
$1.46M
Revenue Growth
n/a
P/S Ratio
0.37
Revenue / Employee
$121,979
Employees
12
Market Cap
8.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58.47K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Equity Holdings | 47.15M |
| Precipio | 17.41M |
| Evogene | 9.45M |
| Evaxion Biotech | 3.30M |
| Exicure | 500.00K |
| BioRestorative Therapies | 377.00K |
| Eyenovia | 31.83K |
ONCO News
- 6 weeks ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 6 weeks ago - Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewsWire
- 6 weeks ago - Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - GlobeNewsWire
- 7 weeks ago - Crude Oil Rises; Onconetix Shares Spike Higher - Benzinga
- 2 months ago - Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - GlobeNewsWire
- 4 months ago - Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds - GlobeNewsWire
- 4 months ago - Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds - GlobeNewsWire
- 10 months ago - Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors - GlobeNewsWire